alpha-aminopyridine has been researched along with Leiomyosarcoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davare, MA; Davis, LE; Debiec-Rychter, M; Hofmann, NE; Nusser, KD; Pittsenbarger, J; Przybyl, J; van de Rijn, M; Varma, S; Vennam, S | 1 |
| Al-Awar, R; Babichev, Y; Boutros, PC; Datti, A; Dickson, BC; Gladdy, RA; Isaac, M; Kabaroff, L; Prakesch, M; Sun, RX; Uehling, D; Venier, R | 1 |
| Chaire, V; Fourneaux, B; Italiano, A; Karanian, M; Laroche-Clary, A; Lucchesi, C; Pineau, R | 1 |
3 other study(ies) available for alpha-aminopyridine and Leiomyosarcoma
| Article | Year |
|---|---|
Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Cell Line, Tumor; Gene Fusion; Humans; Intracellular Signaling Peptides and Proteins; Lactams; Lactams, Macrocyclic; Leiomyosarcoma; Mice; NIH 3T3 Cells; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Transfection | 2019 |
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Imidazoles; Leiomyosarcoma; Mice, Inbred NOD; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Reproducibility of Results; TOR Serine-Threonine Kinases | 2016 |
Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Leiomyosarcoma; MAP Kinase Kinase Kinases; Mechanistic Target of Rapamycin Complex 2; Mice; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinolines; Rapamycin-Insensitive Companion of mTOR Protein; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |